Article
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Cardiology - 1 Jan 2013
Tomek Aleš, Maťoška Václav, Kolářová Tereza, Neumann Jiří, Srámek Martin, Sarbochová Ivana, Táborský Luděk, Bojar Martin, Goetz Petr, Serebruany Victor L
Abstract excerpt
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is hindered by the risk of bleeding. The main reason for this risk is a narrow therapeutic index and a wide response variability after warfarin treatment. These shortcomings affect clinical outcomes including bleeding complications and may be associated with variant polymorphisms in the CYP2C9...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.